麗珠醫藥(01513.HK)腸溶微丸製備方法獲頒專利證書
麗珠醫藥(01513.HK)公布,收到國家知識產權局頒發就腸溶微丸、其製備方法和包含它的製劑的《發明專利證書》,腸溶微丸從內向外依次包括藥丸芯、隔離層和腸溶層,藥丸芯含有艾普拉唑和/或艾普拉唑的藥學上可接受的鹽和第一輔料。
公司指出,上述發明專利技術目前已應用於公司艾普拉唑微丸腸溶片研發項目中,公司自主研發的艾普拉唑微丸腸溶片已於去年11月獲批開展臨床試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.